Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

mRNA neoantigen cancer vaccine XH001

A therapeutic personalized cancer vaccine consisting of mRNA encoding a patient's tumor-specific neoantigens, with potential immunomodulatory and antineoplastic activities. Upon administration of the mRNA neoantigen cancer vaccine XH001, the mRNA is taken up by and translated into the desired neoantigens in the patient's antigen-presenting cells (APCs), primarily dendritic cells (DCs), and presented by major histocompatibility complex (MHC) molecules on the surface of the APCs. This may activate tumor antigen-specific T cells to kill cancer cells expressing these neoantigens.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:mRNA personalized cancer vaccine XH001
mRNA-based neoantigen cancer vaccine XH001
neoantigen mRNA cancer vaccine XH001
Code name:XH 001
XH-001
XH001
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search